Drug Detail:Inotuzumab ozogamicin (Inotuzumab ozogamicin [ in-oh-tooz-ue-mab-oh-zoe-ga-mye-sin ])
Drug Class: Miscellaneous antineoplastics
Inotuzumab Ozogamicin Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of inotuzumab ozogamicin during breastfeeding. Because inotuzumab ozogamicin is a large protein molecule with a molecular weight of 168,000 Da and its active metabolite is 97% plasma protein bound, the amount in milk is likely to be very low. However, its metabolite, N-acetyl-gamma-calicheamicin, is a small molecule that causes double-stranded DNA breaks that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during inotuzumab ozogamicin therapy for at least 2 months after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Inotuzumab Ozogamicin
CAS Registry Number
635715-01-4
Drug Class
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification